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Osteoclasts (OCs) are a specialized cell subset 
with bone-resorbing capacity that plays a criti-
cal role in normal bone homeostasis (bone re-
modeling), degrading old bones and facilitating 
new bone formation by osteoblasts (Teitelbaum, 
2000). OCs are differentiated from monocyte/
macrophage-lineage hematopoietic precursor 
cells, termed OC precursors (OPs), and previ-
ous studies have revealed key molecular signals, 
such as those mediated by M-CSF and RANKL, 
that regulate OC differentiation (Karsenty and 
Wagner, 2002; Teitelbaum and Ross, 2003).   
In contrast to the detailed information available 
concerning molecular signals for differentiation 
of OC, the factors controlling migration and 
localization of OPs onto the bone surface, the 
site of OC terminal differentiation, are less   
well analyzed. We have recently used intravital   
two-photon microscopy to visualize the bone 
cavity in live mice, and found that sphingosine- 
1-phosphate (S1P), a lipid mediator enriched in 
blood, plays a critical role in controlling the res-
idence stability of OPs on the bone surface via 
the cognate receptor S1P receptor 1 (S1PR1; 
also designated S1P1 or Edg-1; Ishii et al., 2009; 
Klauschen et al., 2009). The mechanisms con-
trolling the initial localization of OPs into the 
bone space or counteracting the tendency of 
S1P to promote movement of OPs from bone 
to blood, however, have not yet been clarified. 
In this paper, we show that bone attraction is 
also contributed to in part by S1P, through a 
distinct but related receptor, S1PR2 (also desig-
nated as S1P2 or Edg-5).
Although both S1PR1 and S1PR2 belong   
to  the  heptahelical  heterotrimeric  G  protein– 
coupled  Edg  receptor  family,  their  signal 
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Sphingosine-1-phosphate (S1P), a lipid mediator enriched in blood, controls the dynamic 
migration of osteoclast (OC) precursors (OPs) between the blood and bone, in part via the 
S1P receptor 1 (S1PR1) which directs positive chemotaxis toward S1P. We show that OPs 
also express S1PR2, an S1P receptor which mediates negative chemotaxis (or chemorepulsion). 
OP-positive chemotaxis is prominent in gradients with low maximal concentrations of  
S1P, whereas such behavior is minimal in fields with high maximal S1P concentrations.  
This reverse-directional behavior is caused by S1PR2-mediated chemorepulsion acting to 
override S1PR1 upgradient motion. S1PR2-deficient mice exhibit moderate osteopetrosis as 
a result of a decrease in osteoclastic bone resorption, suggesting that S1PR2 contributes to 
OP localization on the bones mediated by chemorepulsion away from the blood where S1P 
levels are high. Inhibition of S1PR2 function by the antagonist JTE013 changed the  
migratory behavior of monocytoid cells, including OPs, and relieved osteoporosis in a mouse 
model by limiting OP localization and reducing the number of mature OCs attached to the 
bone surface. Thus, reciprocal regulation of S1P-dependent chemotaxis controls bone 
remodeling by finely regulating OP localization. This regulatory axis may be promising as a 
therapeutic target in diseases affecting OC-dependent bone remodeling.
© 2010 Ishii et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(<107 M) and less marked at higher concentrations (Fig. 1 B). 
In addition, blockade of S1PR1 signaling with pertussis toxin 
led to a reduction in migration below the basal level seen in the 
absence of S1P, suggesting that S1P could have a negative   
effect on cell migration under these conditions. We also found 
that  S1PR2  deficiency  enhanced  positive  S1P  chemotaxis.   
To better analyze the effects of varying S1P concentrations on 
migration, we examined the dynamics of S1P chemotaxis in an 
in vitro image-based system (Fig. 1, C and D). In these experi-
ments, cells were applied in the one chamber and S1P was 
added in the other chamber. In this device, a narrow plateau 
between the chambers generates a linear gradient experienced 
by the cells on the opposite side of the chemokine-filled cham-
ber, and the motility of the cells can be assessed throughout 
transduction  pathways  are  completely  different  (Takuwa, 
2002; Rosen and Goetzl, 2005). S1PR1 (via its associated 
Gi subunit) activates the small G protein Rac and induces 
positive chemotaxis. In contrast, S1PR2 (signaling through 
G12/13) activates another small G protein, Rho. Active Rho 
can inhibit activation of Rac, which can limit S1P-induced 
chemotaxis (Fig. 1 A). It was previously reported that S1PR2-
expressing cells show reduced migration to S1P in vitro 
(Okamoto et al., 2000).
RESULTS AND DISCUSSION
We found that OPs express S1PR2 as well as S1PR1, and the 
positive migratory response to S1P was highly concentration 
dependent, being more vigorous at low S1P concentrations 
Figure 1.  Reciprocal control of S1P che-
motaxis by counteracting the receptors 
S1PR1 and S1PR2. (A) Scheme of function 
and signal transduction of S1PR1 and S1PR2. 
(B) In vitro chemotactic response of BM-MDM 
isolated from wild-type and S1PR2-deficient 
mice. Before the chemotaxis assay, some cells 
were treated with 100 nM pertussis toxin 
(PTX). Error bars represent SD (n = 6, from 
three independent experiments). (C) In vitro 
S1P-directed chemotaxis of RAW264.7 cells 
dynamically visualized using EZ-Taxiscan. 
Cells were loaded in one side of the chamber 
and the other side was filled with medium 
containing indicated concentration of S1P 
(Videos 1–3). Cells migrate into the terrace 
between the loading chambers. The height 
from floor to ceiling of the terrace is 8 µm. 
Bar, 100 µm. (D) Tracking courses from the 
start line of representative cells in low, me-
dium, and high S1P conditions. Each curve 
shows the data from one experiment and 
represents the averaged tracking distance of 
multiple cells over time. The EZ-Taxiscan ex-
periments were independently performed six 
times and the data were largely consistent, 
although the extent of the toward-and-away 
motions of cells in 107 M S1P was variable 
depending on the experiment. Obvious away 
motion could clearly be observed in five of the 
six experiments (62 in 83 total cells), and the 
cells simply stopped in the middle of the 
chamber without clear backward migration in 
one of the six experiments (11 in 83 cells).  
(E) In vitro S1P-directed chemotaxis of 
RAW264.7 cells treated with siRNAs. Cells 
pretreated with control RNA duplex, siRNA 
against S1PR1, or siRNA against S1PR2  
(Videos 4–6) were loaded into the EZ-Taxiscan 
chamber filled with a high concentration of 
S1P (109 M) in the other side. (F) RT-PCR 
detection of S1PR1 and S1PR2 in siRNA-pretreated RAW264.7 cells. Cells were pretreated with control RNA duplex (control siRNA), siRNA against S1PR1 
(S1PR1 siRNA), or siRNA against S1PR2 (S1PR2 siRNA). (G) Migration distance data from microscopic analysis of control (red), S1PR1 knockdown (green), 
and S1PR2 knockdown (blue) cells. The experiments were independently performed three times and the data were largely consistent. Each dot represents 
the mean value of six independent cells and error bars represent SD.JEM VOL. 207, December 20, 2010  2795
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less pronounced and took longer than was the case with the 
S1PR1 agonist SEW2871 (Ishii et al., 2009), although the ef-
fect was statistically significant (Fig. 2 B). Data collected using 
larger imaging fields revealed that there was a significant het-
erogeneity in cellular dynamics that correlated with location 
of the cells within the BM cavity (Fig. S2 and Video 9). 
CX3CR1-EGFP+ cells positioned at the bone surface hardly 
move, suggesting that these cells have already committed to OC 
differentiation. In contrast, cells in the parenchyma move after 
application of JTE013 and, more importantly, the migratory 
their exposure to this chemokine gradient in the imaging 
chamber. RAW264.7 cells, which are often used as a model of 
OPs, readily migrated toward a low maximal concentration of 
S1P (109 M; Fig. 1, C [left] and D [top]; and Video 1) but not 
toward a high maximal S1P concentration (106 M; Fig. 1, C 
[right] and D [bottom]; and Video 3). Strikingly, at an inter-
mediate concentration, cells first moved up the S1P gradient 
but then arrested this movement and began to migrate back in 
the opposite direction in nearly all cases (Fig. 1, C [middle]   
and D [middle]; and Video 2). These data reveal that at high 
S1P concentrations, RAW264.7 cells respond by chemorepul-
sion rather than chemoattraction.
RNA  interference  was  used  to  examine  the  roles  of 
S1PR1 and S1PR2 in these S1P concentration-dependent 
behaviors (Fig. 1, E and G). Cells were treated with siRNAs 
targeting S1PR1 or S1PR2 and put in a high S1P concentra-
tion field (106 M; Fig. 1, E and F). Although control cells 
and S1PR1 knockdown cells were hardly motile, as observed 
in Fig. 1 C (Fig. 1, E [left two panels] and G; and Videos 4 
and 5), some of the cells treated with siRNA targeting S1PR2 
could migrate vigorously, irrespective of the high S1P con-
centration (Fig. 1, E [right] and G; and Video 6). We also 
confirmed that S1PR2-deficient primary cultured OPs can 
efficiently move toward a high S1P concentration (Fig. S1), 
establishing that S1PR2 expressed on OPs is indeed func-
tional and that this receptor is responsible for the chemore-
pulsive behavior of these cells (Fig. 1, B and C). These results 
clearly demonstrate that OPs express two counteracting re-
ceptors for S1P: forward movement, promoting S1PR1, and 
backward movement, promoting S1PR2. The migratory be-
havior of OPs is thus finely regulated by the balance of the 
reciprocal functions of these two receptors and their differen-
tial activity at distinct concentrations of S1P.
To investigate whether S1PR2 affects OP migration   
in vivo as these in vitro studies would imply, we performed 
intravital two-photon imaging of calvaria bones (Mazo et al., 
2005; Ishii et al., 2009) and examined the migratory behavior 
of monocytoid cells resident in the marrow spaces, including 
OPs. We used CX3CR1-EGFP knockin (heterozygous) mice 
(Jung et al., 2000; Niess et al., 2005), in which monocyte- 
lineage cell types predominantly expressed EGFP. We have 
previously  confirmed  that  TRAP  (tartrate-resistant  acid 
phosphate)-positive mature OCs expressed EGFP in these ani-
mals (Ishii et al., 2009) and, in addition, we confirmed that 
EGFP+ cells (but not EGFP) can efficiently differentiate 
into OC-like cells in vitro upon stimulation with RANKL 
(Fig. S2). Both of these results strongly suggest that EGFP+ 
cells contain OPs.
CX3CR1-EGFP–positive cells present in BM stromal lo-
cations or at the bone surface were generally stationary under 
control conditions (Fig. 2 A, top; and Video 7). In contrast, a 
subset of the labeled cells became motile 2 h after the intrave-
nous application of 3 mg/kg JTE013 (Osada et al., 2002), a 
potent antagonist for the S1PR2 receptor (Fig. 2 A, bottom; 
and Video 8), with some of the mobilized cells entering the 
blood circulation. The cell-mobilizing effect of JTE013 was 
Figure 2.  In vivo S1PR2-mediated migration control of OP mono-
cytes visualized using intravital two-photon imaging. (A) Intravital 
two-photon imaging of mouse skull bone tissues of heterozygous 
CX3CR1-EGFP knockin mice, in the absence (vehicle; Video 7) or presence 
(Video 8) of 3 mg/kg of the S1PR2 antagonist JTE013. CX3CR1-EGFP–
positive cells appear green. The microvasculature was visualized by intra-
venous injection of 70 kD dextran–conjugated Texas red (red; left). The 
movements of CX3CR1-EGFP–positive cells were tracked for 10 min 
(right). Colored lines show the associated trajectories of cells. Bars, 50 µm. 
(B) Summary of mean velocity of CX3CR1-EGFP–positive cells treated with 
JTE (red circle) or vehicle (blue square). Data points (n = 252 for vehicle 
and n = 237 for JTE013) represent individual cells compiled from six inde-
pendent experiments, and error bars represent SD. (C) Effect of the S1PR2 
antagonist JTE013 on the composition of peripheral mononuclear cells. 
Peripheral mononuclear cells collected from wild-type and S1PR2/ mice 
administered vehicle (C) or JTE013 (J) were stained with anti-CD3 or anti-
CD11b. Absolute numbers of CD3+ T cells or CD11b+ monocytoid cells are 
described in the figure. Each bar represents the mean value derived from 
three independent experiments and error bars represent SD.2796 S1P chemorepulsion of osteoclasts in vivo | Ishii et al.
bone resorption and moderate osteopetrosis. Because the ex-
pression of S1PR2 is high in monocytoid OPs and is hardly 
detected in osteoblast-lineage cells (unpublished data), and 
because S1PR2 deficiency did not alter the capacity of OP   
to differentiate into OCs (Fig. S1), this result indicates that 
S1PR2-mediated chemorepulsion of OPs in response to the 
high blood S1P concentration contributes to their localiza-
tion at the bone surface and promotes osteoclastogenesis   
in vivo.
This newly revealed role of S1PR2-mediated control of 
OP migration prompted us to examine their therapeutic im-
plications. i.p. administration of RANKL induces substantial 
osteoporosis within 2 d (Tomimori et al., 2009). We added 
daily administration of 3 mg/kg of the S1PR2 antagonist 
JTE013 to this regimen and examined the effect on bone 
mineral density (Fig. 3 C). Addition of JTE013 significantly 
reversed the bone density loss induced by RANKL adminis-
tration (Fig. 3 C, left) by limiting osteoclastic bone resorption 
(Fig. 3 C, right, E.S./B.S.). This therapeutic effect of JTE013 
was  absent  in  S1PR2-deficient  mice,  suggesting  that  the 
function of JTE013 is dependent on this receptor. We also 
tested the effect of JTE013 by using ovariectomized mice, a 
conventional  model  for  postmenopausal  osteoporosis,  and 
confirmed the significant therapeutic potentials (Fig. S3).
We  have  previously  shown  that  the  S1P–S1PR1  axis 
contributes to recirculation of OPs into the blood stream 
(thus acting as a circulation-attractive factor), whereas bone-
attractive factors have not been fully elucidated. In this study, 
activities of cells around sinusoids are significantly higher than 
those of cells in the parenchyma around large collecting   
venules. Together, these findings suggest that sinusoids are the 
plausible locations for mobilization of these cells.
Consistent with these findings, we also observed an ele-
vated percentage and absolute number of monocytoid cells in 
peripheral blood from JTE013-treated mice (Fig. 2 C). This 
phenomenon was largely absent in S1PR2-deficient mice, 
suggesting that the effect of JTE013 is exclusively mediated 
by S1PR2. These results are consistent with the idea that an 
S1PR2 antagonist can block OP chemorepulsion mediated 
by the high S1P concentration in blood vessels, facilitating 
the recirculation of OPs.
To evaluate the in vivo impact of such S1PR2-mediated 
chemorepulsion of OPs on bone remodeling, we examined 
mice deficient in S1PR2 (Kono et al., 2004). Morphohisto-
metric analyses using µCT showed that femora of mice geno-
typed as S1PR2 were moderately osteopetrotic, compared 
with those of control littermates (Fig. 3 A). Bone tissue den-
sity (Fig. 3 B, B.V./T.V.) of S1PR2/ mice was significantly 
higher than that of controls, and concordantly trabecular den-
sity (Fig. 3 B, Tb.N.) was increased in S1PR2/ bones. 
Conventional bone morphohistometrical analyses demon-
strated a significant decrease in osteoclastic bone resorption 
(Fig. 3 C, E.S./B.S.) in S1PR2/ bones, whereas osteoblast 
formation was not significantly affected. These results clearly 
suggest that OC attachment to and function on the bone sur-
face was impaired in S1PR2/ animals, leading to reduced 
Figure 3.  In vivo impact of S1PR2 on bone re-
modeling. (A) Morphohistometric analyses of control 
and S1PR2-deficient (S1PR2/) littermates. Femoral 
bone samples were analyzed by cone-beam µCT (top) 
and conventional histological examination (bottom). 
Bars: (top) 1 mm; (bottom) 200 µm. (B) Summary of 
the data of bone matrix density (bone volume/tissue 
volume = B.V./T.V.), trabecular thickness (Tb.Th.), tra-
becular density (Tb.N.; calculated from µCT images), 
osteoblast surface per bone surface (Ob.S./B.S.), and 
osteoclastic erosion surface per bone surface (E.S./
B.S.; calculated by conventional morphohistometrical 
analyses). Error bars represent SD. n = 3 for each 
(from three littermates). (C) Therapeutic effect of 
S1PR2 antagonist JTE013 on osteoclastic bone re-
sorptive changes. Femurs were collected from each 
mouse (wild-type and S1PR2/) after three different 
treatments: PBS + vehicle, RANKL + vehicle, and 
RANKL + JTE013. RANKL was dissolved in PBS, and 
JTE013 was dissolved in a vehicle (PBS containing 5% 
acidified DMSO and 3% fatty acid–free BSA). Mice 
were i.p. injected with PBS or RANKL, and with JTE or 
vehicle, every day for 2 d. Bone samples were ana-
lyzed by cone-beam µCT and conventional morpho-
histological examination. Data of bone matrix density 
(B.V./T.V.) calculated from µCT images (left) and os-
teoclastic erosion surface per bone surface (E.S./B.S.) 
calculated by conventional morphohistometrical 
analyses (right) were shown. Error bars represent SD. 
n = 3 for each (from three littermates).JEM VOL. 207, December 20, 2010  2797
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cell were pretreated with siRNAs targeting S1PR1 or S1PR2 (ON-TARGET 
plus siRNA library; Thermo Fisher Scientific) using a conventional transfec-
tion reagent (Lipofectamine 2000; Invitrogen).
In vitro chemotaxis chamber assay. Chemotactic migration of cells was 
measured in a modified Boyden chamber as described previously (Okamoto 
et al., 2000).
EZ-Taxiscan chemotaxis assay. Chemotaxis experiments were also con-
ducted in an EZ-Taxiscan chamber according to the manufacturer’s protocol 
(Effector Cell Institute). The EZ-Taxiscan is a visually accessible chemotac-
tic chamber, in which one compartment, containing ligand (S1P), and   
another compartment, containing cells, are connected by a microchannel.   
A  stable  concentration  gradient  of  chemoattractant  can  be  reproducibly 
formed and maintained through the channel without medium flow. Phase-
contrast images of migrating cells were acquired at 1-min intervals. Sequen-
tial image data were processed with ImageJ (National Institutes of Health 
[NIH]), equipped with an add-on program, MT Track J.
Mice. C57BL/6 mice and CX3CR1-EGFP knockin mice (Jung et al., 2000) 
were obtained from The Jackson Laboratory. S1PR2-defiicient mice (Kono 
et al., 2004) were obtained from R.L. Proia (National Institute of Diabetes 
and Digestive and Kidney Diseases, NIH, Bethesda, MD). All mice were bred 
and maintained under specific pathogen-free conditions at animal facilities of 
NIH and Osaka University, and all the animal experiments were performed   
according  to  NIH  institutional  guidelines  and  Osaka  University  animal   
experimental guidelines under approved protocols. Mutant mice were geno-
typed by PCR. All mice were housed and handled according to the institu-
tional guidelines under approved protocols.
Two-photon intravital bone tissue imaging. Intravital microscopy of 
mouse calvaria bone tissues was performed using a protocol modified from a 
previous study (Ishii et al., 2009). Mice were anesthetized with isoflurane   
(Escain; 2.5% vaporized in an 80:20 mixture of O2 and air), and the hair in the 
neck and scalp was removed with hair removal lotion (Epilat). The fronto-
parietal skull was exposed and the mouse head was immobilized in a custom-
made stereotactic holder. A catheter was placed into the tail vein with a 
30-gauge needle attached to PE-10 tubing (BD). The imaging system was 
composed of a multiphoton microscope (SP5; Leica) driven by a laser (MaiTai 
HP Ti:Sapphire; Spectraphysics) tuned to 880 nm and an upright microscope 
(DM6000B; Leica) equipped with a 20× water immersion objective (HCX 
APO, N.A. 1.0; Leica). The microscope was enclosed in an environmental 
chamber in which anesthetized mice were warmed by heated air. Fluorescent 
cells were detected through a bandpass emission filter at 525/50 nm (for 
EGFP). Vessels were visualized by injecting 70 kD of Texas red–conjugated 
dextran (detected using a 650/50 nm filter) i.v. immediately before imaging. 
In some experiments, 3 mg/kg JTE013 (Tocris Bioscience) dissolved in a ve-
hicle (PBS containing 5% acidified DMSO and 3% fatty acid–free BSA) or 
vehicle only was injected during the imaging. Image stacks were collected at a 
3-µm vertical step size at a depth of 100–150 µm below the skull bone surface. 
For 3D videos, four sequential image stacks were acquired at 3-µm z spacing   
to cover a volume of 154 µm × 154 µm × 9.0 µm. The time resolution was   
1 min. Raw imaging data were processed with Imaris (Bitplane) with a Gaussian 
filter for noise reduction. Automatic 3D object tracking with Imaris Spots was 
aided with manual corrections to retrieve cell spatial coordinates over time.
Mouse  treatment  experiment.  Nine  8-wk-old  female,  wild-type,  or 
S1PR2/ mice were injected i.p. with PBS, 2 mg/kg GST-RANKL dis-
solved in PBS (Tomimori et al., 2009), and 2 mg/kg GST-RANKL and   
3 mg/kg JTE013 (dissolved in PBS containing 5% acidified DMSO and 3% 
fatty acid-free BSA) for 2 d. The mice were then sacrificed and femurs were 
excised and subjected to histomorphometrical analyses.
Histomorphometry  of  bone  tissues.  Trabecular  bone  morphometry 
within the metaphyseal region of distal femur was quantified using micro-CT 
we demonstrate a complex regulatory system in which S1P 
also acts as a bone attractant in certain conditions (actually 
functioning as a circulation repellant) through a different cog-
nate receptor, S1PR2. In contrast to several chemokines that 
have already been reported to be important for OP localiza-
tion, such as CCL2 (Binder et al., 2009), CCL9 (Yang et al., 
2006), CXCL1 (Onan et al., 2009), and CXCL12 (Gronthos 
and Zannettino, 2007), we assume that the S1P–S1PR1/
S1PR2 reciprocal axes contribute to regulating the initial entry/
exit of OPs across the border of BM vasculature, rather than   
attachment at the bone surface by itself.
Given these data, we suggest the following model for S1P-
mediated localization control of OPs in bone tissues in vivo 
(Fig. S3). As with other tissues and organs, the S1P concentra-
tion in bone tissues is relatively low (Maeda et al., 2010), 
forming a substantial S1P gradient between BM tissues   
(parenchyma), the sinusoids, and blood vessels, which is a pre-
requisite for S1P chemotaxis in situ. Because S1PR1 is readily 
down-regulated by endocytosis in a high S1P environment, OPs 
in blood vessels could enter into bones by S1PR2-mediated   
repulsion, although S1PR2-mediated OP entry into BM has 
not been fully demonstrated in the present experiments.   
In addition, we do not assume this is the only mechanism reg-
ulating OP entry but rather consider several bone-enriched 
chemokines, CXCL12 chief among them (Gronthos and 
Zannettino, 2007), to also be involved in bone recruitment, 
with S1PR2-mediated chemorepulsion facilitating this pro-
cess. Once they entered into the parenchyma, S1PR1 would 
be reexpressed on the cell surface, prompting potential reentry 
into the circulation if other factors (chemokines and adhesion 
molecules) at the bone surface do not override this chemoat-
tractive effect. Although it cannot be measured precisely, S1P 
concentration in BM sinusoids, because of leakage across en-
dothelial barriers, might be expected to be intermediate be-
tween parenchymal tissues and blood vessels. If this is the case, 
it is plausible that OPs can exit from bone tissue via the sinu-
soids, whose S1P concentration can only activate S1PR1 but 
not S1PR2. The concept that sinusoids are the place of OP 
mobilization agrees with our observation that sinusoidal cells 
have high motility in JTE-treated BM (Fig. S2).
This study clearly demonstrates that reciprocal actions of 
two S1P receptors regulate the steady-state migration propensi-
ties of OPs, constituting a versatile cycle that may play a crucial 
role  in  control  of  osteoclastogenesis  and  bone  remodeling.   
Although therapeutics in bone-resorptive disorders have so far 
been targeted mature OCs (such as bisphosphonates) or late 
OPs fairly committed to OC differentiation (such as deno-
sumab, i.e., anti-RANKL neutralizing antibody), treatment tar-
geting monocytoid early OPs, such as S1P modulators, might 
be promising as a novel line of treatment in these disorders.
MATERIALS AND METHODS
Cell  culture.  RAW264.7,  a  mouse  macrophage/monocyte  lineage  cell 
line, and mouse BM-derived M-CSF–dependent monocytes (BM-MDM), 
containing OP cells, were cultured as previously described (Ishii et al., 2006). 
To stimulate osteoclastogenesis, 50 ng/ml RANKL (PeproTech) was added 
to the medium and the cells were incubated for 3–4 d. In some experiments, 2798 S1P chemorepulsion of osteoclasts in vivo | Ishii et al.
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(ScanXmate-RX; Comscantechno Inc.). 3D microstructural image data were 
reconstructed, and structural indices, such as B.V./T.V., Tb.Th., and Tb.N., 
were calculated using TRI/3D-BON software (RATOC Systems). Bone mor-
phometric analysis was performed as previously described (Parfitt et al., 1987).
Flow cytometry. All reagents were purchased from BD. To examine the 
composition of peripheral blood mononuclear cells, blood was collected 
from  the  retroorbital  plexus  with  a  heparinized  glass  pipette  from  mice 
treated i.p. 2 h previously with 3 mg/kg JTE013 or vehicle. After removing 
the red blood cells by ACK lysis buffer (Invitrogen), cells were stained with 
FITC-conjugated  anti-CD11b  and  PE-Cy7–conjugated  anti-CD3,  using 
conventional methods. Flow cytometric data were collected on a FACS-
Canto II (BD) and analyzed with FlowJo software (Tree Star, Inc.).
Statistics. The Mann-Whitney rank sum test was used to calculate p-values 
for highly skewed distributions. For Gaussian-like distributions, two-tailed 
Student’s t tests were used.
Online supplemental material. Fig. S1 shows chemotaxis and in vitro 
osteoclastogenesis of S1PR2 knockout OPs. Fig. S2 shows in vivo S1PR2-
mediated migration control of CX3CR1+ OP monocytes visualized using 
intravital two-photon imaging. Fig. S3 shows the therapeutic effect of 
S1PR2 antagonist JTE013 on ovariectomy-induced osteoporosis and sche-
matic model for S1P-mediated localization control of OPs in bone tissues. 
Videos 1–6 show in vitro chemotaxis of RAW264.7 cells toward an S1P 
gradient detected using the EZ-Taxiscan device. Videos 7 and 8 show intra-
vital two-photon imaging of mouse skull bone tissues of CX3CR1-EGFP 
hetero knockin mice. Video 9 shows intravital two-photon imaging (broad 
visual field) of mouse skull bone tissues of CX3CR1-EGFP heterozygous 
knockin mice. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20101474/DC1.
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